logo-loader

IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic

Published: 00:26 09 Jan 2019 EST

IGF Oncology CEO Hugh McTavish sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

IGF Oncology is a biotech company developing targeted anti-cancer drugs. Its lead drug, IGF-MTX, targets blood cancer, and is currently in clinical trials at the Mayo Clinic.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 53 minutes ago